Phase 2
Completed N=80
Biomarker Strategies for Medication-Enhanced Cognitive Training in Schizophrenia
Source: ClinicalTrials.gov NCT01555697 ↗Enrolled (actual)
80
Serious AEs
0.0%
Results posted
Aug 2020
Primary outcomePrimary: Prepulse Inhibition — 30.4; 25.5; 23.7; 2.6 % inhibition of startle
Summary
Cognitive training is moderately effective at reducing symptoms and improving life function in schizophrenia patients. The present application develops a strategy for increasing the effectiveness of cognitive training through the use of pro-cognitive medications. Specific biomarkers will be studied that identify patients most sensitive to these pro-cognitive medications, to test the feasibility of using these biomarkers in a large clinical trial of medication-enhanced cognitive training in schizophrenia.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Prepulse Inhibition |
30.4; 25.5; 23.7; 2.6; -1.7; -9.7 | — |
| SECONDARY MATRICS |
40.4; 53.4; 41.1; 56.3; 34.2; 48.6 | — |
Eligibility Criteria
Inclusion Criteria
- A diagnosis of schizophrenia or schizoaffective disorder - depressed type
Exclusion Criteria
- Age range,
- Current alcohol or drug abuse
Data sourced from ClinicalTrials.gov (NCT01555697). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.